Clover Health Investments, Corp. (CLOV)

Clover Health Investments Stock Forecast

Stock Price Forecast

The 3 analysts that cover Clover Health Investments stock have a consensus rating of "Strong Buy" and an average price target of $4.83, which forecasts a 58.36% increase in the stock price over the next year. The lowest target is $4 and the highest is $6.

Price Target: $4.83 (+58.36%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$4.00	$4.83	$4.50	$6.00
Change	+31.15%	+58.36%	+47.54%	+96.72%

* Price targets were last updated on Mar 3, 2025.

Analyst Ratings

The average analyst rating for Clover Health Investments stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Feb '25	Mar '25	Apr '25	May '25	Jun '25	Jul '25
Strong Buy	1	2	2	2	2	2
Buy	0	0	0	0	0	0
Hold	1	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	2	3	3	3	3	3

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Richard Close Canaccord Genuity	Canaccord Genuity	Strong Buy Maintains $4.2 → $4.5	Strong Buy	Maintains	$4.2 → $4.5	+47.54%	Mar 3, 2025
Matt Hewitt Craig-Hallum	Craig-Hallum	Strong Buy Initiates $6	Strong Buy	Initiates	$6	+96.72%	Dec 17, 2024
Jonathan Yong UBS	UBS	Hold Initiates $4	Hold	Initiates	$4	+31.15%	Oct 7, 2024
Jason Cassorla Citigroup	Citigroup	Hold Maintains $1 → $1.5	Hold	Maintains	$1 → $1.5	-50.82%	Aug 11, 2023
Richard Close Canaccord Genuity	Canaccord Genuity	Strong Buy Maintains $4 → $3	Strong Buy	Maintains	$4 → $3	-1.64%	Mar 6, 2023

More Analyst Ratings

Financial Forecast

Revenue This Year

1.90B

Increased by 38.62%

from 1.37B

Revenue Next Year

2.32B

Increased by 22.21%

from 1.90B

EPS This Year

-0.13

from -0.09

EPS Next Year

-0.13

from -0.13

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	690.02M	1.36B	1.20B	1.26B	1.37B	1.90B	2.32B	2.50B
Revenue Growth	51.74%	97.30%	-11.91%	5.32%	8.52%	38.62%	22.21%	7.75%
EPS	-1.54	-1.42	-0.71	-0.44	-0.09	-0.13	-0.13	-0.01
EPS Growth	-	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	6	6	4

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029
High	2.0B	2.5B	2.7B
Avg	1.9B	2.3B	2.5B
Low	1.8B	2.1B	2.2B

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029
High	44.6%	30.1%	17.1%
Avg	38.6%	22.2%	7.8%
Low	31.3%	9.6%	-5.8%

EPS Forecast

EPS	2025	2026	2027	2028	2029
High	-0.11	-0.11	0.04
Avg	-0.13	-0.13	-0.01
Low	-0.16	-0.15	-0.05

EPS Growth

EPS Growth	2025	2026	2027	2028	2029
High	-	-	-
Avg	-	-	-
Low	-	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.